Impaired immunoresponsiveness in tumor patients.
D000917:Antibody Formation; D000936:Antigen-Antibody Complex; D000937:Antigen-Antibody Reactions; D001402:B-Lymphocytes / Q000276:immunology; D002051:Burkitt Lymphoma / Q000276:immunology; D006689:Hodgkin Disease / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity; D007154:Immune System Diseases; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000209:etiology; D037102:Lectins; D007945:Leukemia, Lymphoid / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D009101:Multiple Myeloma / Q000276:immunology; D009369:Neoplasms / Q000097:blood / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology; D011379:Prognosis; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology
D000936:Antigen-Antibody Complex; D037102:Lectins